These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 24452757

  • 1. Pancreatic NETs: where do we stand now?
    Faivre S, Castellano D, Strosberg J, González E, Salazar R.
    Cancer Metastasis Rev; 2014 Mar; 33(1):361-6. PubMed ID: 24452757
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
    Martins D, Spada F, Lambrescu I, Rubino M, Cella C, Gibelli B, Grana C, Ribero D, Bertani E, Ravizza D, Bonomo G, Funicelli L, Pisa E, Zerini D, Fazio N, IEO ENETS Center of Excellence for GEP NETs.
    Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
    [Abstract] [Full Text] [Related]

  • 7. Targeted agents in treatment of neuroendocrine tumors of pancreas.
    Karampelas IN, Syrigos KN, Saif MW.
    JOP; 2014 Jul 28; 15(4):351-3. PubMed ID: 25076341
    [Abstract] [Full Text] [Related]

  • 8. New target therapies for patients with neuroendocrine tumors of the pancreas.
    Baltogiannis G, Katsios C, Roukos DH.
    Expert Rev Gastroenterol Hepatol; 2011 Oct 28; 5(5):563-6. PubMed ID: 21910571
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Promising advances in the treatment of malignant pancreatic endocrine tumors.
    Jensen RT, Delle Fave G.
    N Engl J Med; 2011 Feb 10; 364(6):564-5. PubMed ID: 21306243
    [No Abstract] [Full Text] [Related]

  • 16. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
    Tijeras-Raballand A, Neuzillet C, Couvelard A, Serova M, de Gramont A, Hammel P, Raymond E, Faivre S.
    Target Oncol; 2012 Sep 10; 7(3):173-81. PubMed ID: 22923165
    [Abstract] [Full Text] [Related]

  • 17. Pancreatic neuroendocrine neoplasms.
    Hörsch D, Bert T, Schrader J, Hommann M, Kaemmerer D, Petrovitch A, Zaknun J, Baum RP.
    Minerva Gastroenterol Dietol; 2012 Dec 10; 58(4):401-26. PubMed ID: 23207615
    [Abstract] [Full Text] [Related]

  • 18. Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.
    Liakakos T, Roukos DH.
    Future Oncol; 2011 Sep 10; 7(9):1025-9. PubMed ID: 21919689
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.